Document Detail

Circulating neuroendocrine markers in patients with prostate carcinoma.
MedLine Citation:
PMID:  10861438     Owner:  NLM     Status:  MEDLINE    
BACKGROUND: Circulating neuroendocrine markers were measured in patients with prostate carcinoma (PC), prostatic intraepithelial neoplasia (PIN), and benign prostatic hypertrophy (BPH) with the goal to: 1) evaluate the differences in the expression of these markers in patients with benign, premalignant, and primary or metastatic PC; 2) evaluate their prognostic significance; 3) compare values in patients with hormone-naive and hormone-refractory disease; and 4) assess changes after androgen deprivation or chemotherapy. METHODS: Serum neuron specific enolase (NSE) (immunoradiometric assay) and plasma chromogranin A (CgA) (enzyme-linked immunoadsorbent assay) were evaluated in 141 patients with BPH, 54 patients with PIN, and 159 patients with PC; 119 patients were bearing hormone-naive disease and 40 were bearing hormone-refractory disease. CgA was monitored in 31 patients submitted to androgen deprivation and in 24 patients receiving chemotherapy. RESULTS: Supranormal CgA was observed more frequently in patients with American Urologic Association (AUA) Stage D2 disease (45.5%) compared with those with Stage D1 disease (33.3%), Stage C disease (16.7%), Stage A/B disease (18.8%), PIN (25.9%), and BPH (17.0%) (P < 0.02). Supranormal NSE did not change in any of the patient subgroups. Elevated CgA was observed in 36.0% of patients with metastases who had hormone-naive disease and in 45.0% of patients with hormone-refractory disease (P value not significant). Supranormal NSE and CgA values were predictors for poor prognosis in patients with hormone-refractory disease. Elevated baseline CgA values decreased > 50% in 1 of 12 patients who received luteinizing hormone-releasing hormone analogs and in 2 of 12 patients who underwent chemotherapy. CONCLUSIONS: CgA appears to reflect the neuroendocrine activity of PC better than NSE. Elevated CgA values correlate with poor prognosis and are scarcely influenced by either endocrine therapy or chemotherapy.
A Berruti; L Dogliotti; A Mosca; M Bellina; M Mari; M Torta; R Tarabuzzi; E Bollito; D Fontana; A Angeli
Related Documents :
15902278 - Neurovascular bundle block as predictor of postoperative erectile function after radica...
21390148 - Single center experience of capsule endoscopy in patients with obscure gastrointestinal...
21557228 - Empty nose syndrome: radiologic findings and treatment outcomes of endonasal microplast...
19608618 - Phase ii, two-stage, single-arm trial of the histone deacetylase inhibitor (hdaci) romi...
17822528 - Antipolymer antibody in italian fibromyalgic patients.
23109448 - Validation and comparison of simple noninvasive models for the prediction of liver fibr...
Publication Detail:
Type:  Journal Article; Research Support, Non-U.S. Gov't    
Journal Detail:
Title:  Cancer     Volume:  88     ISSN:  0008-543X     ISO Abbreviation:  Cancer     Publication Date:  2000 Jun 
Date Detail:
Created Date:  2000-09-11     Completed Date:  2000-09-11     Revised Date:  2006-11-15    
Medline Journal Info:
Nlm Unique ID:  0374236     Medline TA:  Cancer     Country:  UNITED STATES    
Other Details:
Languages:  eng     Pagination:  2590-7     Citation Subset:  AIM; IM    
Copyright Information:
Copyright 2000 American Cancer Society.
Dipartimento di Scienze Cliniche e Biologiche Università di Torino, Oncologia Medica, Medicina Interna, Azienda Ospedaliera San Luigi, Orbassano, Italy.
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Aged, 80 and over
Analysis of Variance
Carcinoma / blood*,  mortality
Chromogranin A
Chromogranins / blood*
Cohort Studies
Middle Aged
Phosphopyruvate Hydratase / blood*
Prostatic Hyperplasia / blood*,  mortality
Prostatic Intraepithelial Neoplasia / blood*,  mortality
Prostatic Neoplasms / blood*,  mortality
Statistics, Nonparametric
Survival Rate
Tumor Markers, Biological / blood*
Reg. No./Substance:
0/Chromogranin A; 0/Chromogranins; 0/Tumor Markers, Biological; EC Hydratase

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Previous Document:  Clinical characteristics of clear cell carcinoma of the ovary: a distinct histologic type with poor ...
Next Document:  MIB-1 as a proliferative marker in transitional cell carcinoma of the bladder: clinical significance...